Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

New information from two case control studies of the transdermal contraceptive (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) indicates no increased risk of heart attack or stroke for women who choose the patch, but data conflict on the occurrence of venous thromboembolism (VTE).

Bulletin: New information emerges on risks associated with Ortho Evra